EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Therefore, if clients were to switch manufacturers, it would require establishing a new cell line that ... sites are already involved in Novo Nordisk manufacturing contracts, which are largely ...
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Novo Nordisk has spared no expense in expanding its pharmaceutical reach and scope. In addition to adding new factories to ramp up production to meet demand for Ozempic and Wegovy, the company’s ...
GlobalData on MSN1d
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirlNovo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, intended to serve biotechs and pharmas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback